Favaretto, Adolfo, Francesco Grossi, Alessandro Morabito, and Roberto Ravasio. “Costs of Adverse Events Associated With Afatinib, Erlotinib, and Gefitinib First-Line Therapies in Advanced Non-Small-Cell Lung Cancer Harboring EGFR-Activating Mutations: Il Costo Degli Eventi Avversi Associati Ad Afatinib, Erlotinib E Gefitinib Nel Trattamento Del Tumore Del Polmone Non a Piccole Cellule Con Mutazione EGFR”. Global and Regional Health Technology Assessment 4, no. 1 (July 8, 2017): 187–196. Accessed July 3, 2024. https://journals.aboutscience.eu/index.php/grhta/article/view/394.